Effects of rivastigmine on cognitive function in dementia with lewy bodies: A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system

Keith A. Wesnes, I. G. Mckeith, R. Ferrara, M. Emre, T. Del Ser, P. F. Spano, A. Cicin-Sain, R. Anand, R. Spiegel

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

This study was designed to assess the effects of rivastigmine (Exelon®) on the cognitive functioning of patients suffering from dementia with Lewy bodies. This was a prospective, multi-centre, randomised, double-blind, placebo-controlled exploratory study conducted at sites in the UK, Spain and Italy. The treatment period was 20 weeks with a 3-week posttreatment follow-up. The primary outcome measures were the Cognitive Drug Research (CDR) computerised assessment system and the Neuropsychiatric Inventory. Testing was conducted prior to dosing and then again at weeks 12, 20 and 23. Analysis of the data from the 92 patients who completed the study identified a significant pattern of benefits of rivastigmine over placebo on the CDR system. These benefits were seen on tests of attention, working memory and episodic secondary memory. Taking attention for example, patients given placebo showed a significant deterioration from predosing scores at 12 and 20 weeks, whereas patients on rivastigmine performed significantly above their predosing levels. These effects were also large in magnitude, the decline under placebo at week 12 being 19%, while the improvement under rivastigmine was 23%. The clinical relevance of this 23% improvement was that it took the patients 33% towards being normal for their age on this assessment of attention. These benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory. Three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.

Original languageEnglish
Pages (from-to)183-192
Number of pages10
JournalDementia and Geriatric Cognitive Disorders
Volume13
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Rivastigmine
Lewy Body Disease
Cognition
Placebos
Research
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Equipment and Supplies
Episodic Memory
Short-Term Memory
Spain
Italy

Keywords

  • Attention
  • Cognitive Drug Research computerised assessment system
  • Dementia with Lewy bodies
  • Rivastigmine
  • Secondary memory
  • Working memory

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Effects of rivastigmine on cognitive function in dementia with lewy bodies : A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. / Wesnes, Keith A.; Mckeith, I. G.; Ferrara, R.; Emre, M.; Del Ser, T.; Spano, P. F.; Cicin-Sain, A.; Anand, R.; Spiegel, R.

In: Dementia and Geriatric Cognitive Disorders, Vol. 13, No. 3, 2002, p. 183-192.

Research output: Contribution to journalArticle

Wesnes, Keith A. ; Mckeith, I. G. ; Ferrara, R. ; Emre, M. ; Del Ser, T. ; Spano, P. F. ; Cicin-Sain, A. ; Anand, R. ; Spiegel, R. / Effects of rivastigmine on cognitive function in dementia with lewy bodies : A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. In: Dementia and Geriatric Cognitive Disorders. 2002 ; Vol. 13, No. 3. pp. 183-192.
@article{3ba0eb6712534e68a042bbdaa3a07b8d,
title = "Effects of rivastigmine on cognitive function in dementia with lewy bodies: A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system",
abstract = "This study was designed to assess the effects of rivastigmine (Exelon{\circledR}) on the cognitive functioning of patients suffering from dementia with Lewy bodies. This was a prospective, multi-centre, randomised, double-blind, placebo-controlled exploratory study conducted at sites in the UK, Spain and Italy. The treatment period was 20 weeks with a 3-week posttreatment follow-up. The primary outcome measures were the Cognitive Drug Research (CDR) computerised assessment system and the Neuropsychiatric Inventory. Testing was conducted prior to dosing and then again at weeks 12, 20 and 23. Analysis of the data from the 92 patients who completed the study identified a significant pattern of benefits of rivastigmine over placebo on the CDR system. These benefits were seen on tests of attention, working memory and episodic secondary memory. Taking attention for example, patients given placebo showed a significant deterioration from predosing scores at 12 and 20 weeks, whereas patients on rivastigmine performed significantly above their predosing levels. These effects were also large in magnitude, the decline under placebo at week 12 being 19{\%}, while the improvement under rivastigmine was 23{\%}. The clinical relevance of this 23{\%} improvement was that it took the patients 33{\%} towards being normal for their age on this assessment of attention. These benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory. Three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.",
keywords = "Attention, Cognitive Drug Research computerised assessment system, Dementia with Lewy bodies, Rivastigmine, Secondary memory, Working memory",
author = "Wesnes, {Keith A.} and Mckeith, {I. G.} and R. Ferrara and M. Emre and {Del Ser}, T. and Spano, {P. F.} and A. Cicin-Sain and R. Anand and R. Spiegel",
year = "2002",
doi = "10.1159/000048651",
language = "English",
volume = "13",
pages = "183--192",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effects of rivastigmine on cognitive function in dementia with lewy bodies

T2 - A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system

AU - Wesnes, Keith A.

AU - Mckeith, I. G.

AU - Ferrara, R.

AU - Emre, M.

AU - Del Ser, T.

AU - Spano, P. F.

AU - Cicin-Sain, A.

AU - Anand, R.

AU - Spiegel, R.

PY - 2002

Y1 - 2002

N2 - This study was designed to assess the effects of rivastigmine (Exelon®) on the cognitive functioning of patients suffering from dementia with Lewy bodies. This was a prospective, multi-centre, randomised, double-blind, placebo-controlled exploratory study conducted at sites in the UK, Spain and Italy. The treatment period was 20 weeks with a 3-week posttreatment follow-up. The primary outcome measures were the Cognitive Drug Research (CDR) computerised assessment system and the Neuropsychiatric Inventory. Testing was conducted prior to dosing and then again at weeks 12, 20 and 23. Analysis of the data from the 92 patients who completed the study identified a significant pattern of benefits of rivastigmine over placebo on the CDR system. These benefits were seen on tests of attention, working memory and episodic secondary memory. Taking attention for example, patients given placebo showed a significant deterioration from predosing scores at 12 and 20 weeks, whereas patients on rivastigmine performed significantly above their predosing levels. These effects were also large in magnitude, the decline under placebo at week 12 being 19%, while the improvement under rivastigmine was 23%. The clinical relevance of this 23% improvement was that it took the patients 33% towards being normal for their age on this assessment of attention. These benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory. Three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.

AB - This study was designed to assess the effects of rivastigmine (Exelon®) on the cognitive functioning of patients suffering from dementia with Lewy bodies. This was a prospective, multi-centre, randomised, double-blind, placebo-controlled exploratory study conducted at sites in the UK, Spain and Italy. The treatment period was 20 weeks with a 3-week posttreatment follow-up. The primary outcome measures were the Cognitive Drug Research (CDR) computerised assessment system and the Neuropsychiatric Inventory. Testing was conducted prior to dosing and then again at weeks 12, 20 and 23. Analysis of the data from the 92 patients who completed the study identified a significant pattern of benefits of rivastigmine over placebo on the CDR system. These benefits were seen on tests of attention, working memory and episodic secondary memory. Taking attention for example, patients given placebo showed a significant deterioration from predosing scores at 12 and 20 weeks, whereas patients on rivastigmine performed significantly above their predosing levels. These effects were also large in magnitude, the decline under placebo at week 12 being 19%, while the improvement under rivastigmine was 23%. The clinical relevance of this 23% improvement was that it took the patients 33% towards being normal for their age on this assessment of attention. These benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory. Three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.

KW - Attention

KW - Cognitive Drug Research computerised assessment system

KW - Dementia with Lewy bodies

KW - Rivastigmine

KW - Secondary memory

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=0036118858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036118858&partnerID=8YFLogxK

U2 - 10.1159/000048651

DO - 10.1159/000048651

M3 - Article

C2 - 11893841

AN - SCOPUS:0036118858

VL - 13

SP - 183

EP - 192

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 3

ER -